D.A. Davidson & Co. Supernus Pharmaceuticals, Inc. Transaction History

D.A. Davidson & Co.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 05, 2019	SELL	$25.47 - $33.37 $470,252 - $616,110	-18,463 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $119 - $155	4 Added 0.02%	18,463 $611,000
Q1 2019 May 13, 2019	BUY	$32.77 - $41.99 $61,214 - $78,437	1,868 Added 11.26%	18,459 $647,000
Q4 2018 Jan 29, 2019	SELL	$30.84 - $49.51 $21,495 - $34,508	-697 Reduced 4.03%	16,591 $551,000
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $3,458 - $4,580	-81 Reduced 0.47%	17,288 $870,000
Q2 2018 Aug 02, 2018	BUY	$44.1 - $59.85 $40,616 - $55,121	921 Added 5.6%	17,369 $1.04 Million
Q1 2018 May 04, 2018	BUY	$37.15 - $46.9 $36,295 - $45,821	977 Added 6.32%	16,448 $753,000
Q4 2017 Feb 08, 2018	BUY	$36.4 - $42.6 $7,716 - $9,031	212 Added 1.39%	15,471 $617,000
Q3 2017 Nov 08, 2017	BUY	$36.75 - $49.65 $24,365 - $32,917	663 Added 4.54%	15,259 $610,000
Q2 2017 Aug 11, 2017	BUY	N/A	14,596	14,596 $0

286

60.7M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.14B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.